NCT06587568

Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases

Mobile Chat Messaging Plus Screening-based Brief Alcohol Intervention for Patients With Chronic Liver Diseases: a Pilot Randomised Controlled Trial

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 106 (actual)
• Sponsor: The University of Hong Kong · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of mobile chat messaging for reducing alcohol use among patients with chronic liver diseases. Specific objectives include: 1. To assess whether the eligibility criteria were too restrictive by estimating the eligibility rate 2. To assess how many eligible CLD patients accepted the invitation to participate in the trial 3. To assess the participant retention rate through 6 months after treatment initiation 4. To assess the intervention acceptability in terms of participants' engagement with and rating of the chat messaging intervention. 5. To assess the safety of the intervention 6. To estimate the intervention effect on alcohol use outcomes and liver functions 7. To synthesise data to inform the sample size calculation in the future definitive trial 8. To explore the participants' perception and experiences in the chat-based intervention

Conditions

• Chronic Liver Disease

Interventions

Type	Name	Description
BEHAVIORAL	Mobile chat messaging	A trained counsellor will interact with a participant individually and provide personalised alcohol reduction information and advice via a mobile instant messaging app in real time for 3 months from randomisation.
BEHAVIORAL	Screening, brief intervention and referral to treatment	Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet

Timeline

• Start date: 2024-10-02
• Primary completion: 2025-11-30
• Completion: 2025-12-31
• First posted: 2024-09-19
• Last updated: 2025-05-01

Locations

1 site across 1 country: Hong Kong